# US 2015/0105342 A1 · In vitro method for predicting disease outcome in stage ii colorectal cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105342 A1
- Document ID: US20150105342A1
- Status: Published application
- Kind: A1
- Application number: 14/397,764
- Filed: 2013-04-25
- Published: 2015-04-16
- Earliest claimed: 2012-04-29
- Assignees: Universiteit Maastricht
- Applicants: Universiteit Maastricht; Academisch Ziekenhuis Maastricht; The John Hopkins University
- Inventors: Manon van Engeland; Adriaan Pieter de Bruïne; James Herman
- Web page: https://patentgrep.com/patent/US20150105342A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a method for determining the likelihood of disease outcome of a patient diagnosed with microsatellite stable, stage II colorectal cancer. More in particular, the present invention relates to a method for determining the prognosis of a patient diagnosed with microsatellite stable, stage II colorectal cancer wherein the CpG island methylation status of the promoter of the CHFR gene is determined and wherein methylation of the promoter is indicative of a poor prognosis.

## Claims

### Claim 1

A method for determining the prognosis of a subject diagnosed with microsatellite stable, stage II colorectal cancer, the method comprising:
determining the CpG island methylation status of the promoter of the CHFR gene in the cancer, wherein methylation of the promoter is indicative of a poor prognosis.

### Claim 2 (depends on 1)

The method according to claim 1 wherein the subject also carries a wild-type BRAF gene.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the CpG island methylation status of the promoter of the CHFR gene is determined using Methylation Specific PCR.

### Claim 4 (depends on 3)

The method according to claim 3, wherein at least one primer pair is used selected from the group consisting of primer pairs 1 (SEQ ID NO: 3 and SEQ ID NO: 4) and primer pair 2 (SEQ ID NO: 4 and SEQ ID NO: 6).

### Claim 5 (depends on 1)

The method according to claim 1, further comprising treating the subject with adjuvant therapy.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the adjuvant therapy is adjuvant chemotherapy.

### Claim 7 (depends on 1)

The method according to claim 1, further comprising treating the subject with adjuvant 5-fluorouracil (FU)-based therapy.